Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 13/20 | 0.68 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.68 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.68 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.58 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.57 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | HRH1 | P35367 | 1/20 | 0.57 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10397000 | 0.88 | OPRM1 (0.55) | OPRM1OPRD1OPRK1SLC22A1ABCB1 | |
| Oxalic Acid SCHEMBL6045520 | 0.86 | OPRM1 (0.54) | OPRM1OPRD1OPRK1OPRL1KCNH2 | |
| SCHEMBL9786448 | 0.86 | OPRM1 (0.54) | OPRM1OPRD1OPRK1KCNH2SIGMAR1 | |
| SCHEMBL10478955 | 0.85 | OPRM1 (0.61) | OPRM1OPRD1OPRK1OPRL1SLC22A1 | |
| SCHEMBL10398382 | 0.85 | OPRM1 (0.71) | OPRM1OPRD1OPRK1SLC22A1ABCB1 | |
| SCHEMBL3303683 | 0.85 | OPRM1 (0.80) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL11569033 | 0.84 | OPRM1 (0.78) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL821488 | 0.84 | OPRM1 (0.78) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL9371229 | 0.83 | OPRM1 (0.59) | OPRM1OPRD1OPRK1OPRL1SLC22A1 | |
| Oxalic Acid SCHEMBL10517781 | 0.83 | OPRM1 (0.59) | OPRM1OPRD1OPRK1OPRL1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20210093557-A1 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | ADAPT PHARMA LTD (IE) | 2021-04-01 | — | — | US | claimed |
| US-20200030229-A1 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | Adapt Pharma Limited | 2020-01-30 | — | — | US | claimed |
| EP-3560484-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G.L. Pharma GmbH (AT) | 2019-10-30 | — | — | EP | claimed |
| EP-3423034-B1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G L PHARMA GMBH (AT) | 2019-07-10 | — | — | EP | claimed |
| EP-3423034-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G.L. Pharma GmbH (AT) | 2019-01-09 | — | — | EP | claimed |
| US-10085937-B2 | Nasal drug products and methods of their use | Adapt Pharma Limited (IE) | 2018-10-02 | — | — | US | claimed |
| EP-3349756-A1 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | Adapt Pharma Limited (IE) | 2018-07-25 | — | — | EP | claimed |
| EP-3210596-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G.L. Pharma GmbH (AT) | 2017-08-30 | — | — | EP | claimed |
| WO-2017049181-A1 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | Adapt Pharma Limited (IE) | 2017-03-23 | — | — | WO | claimed |
| US-20170071851-A1 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | INDIVIOR UK LIMITED (GB) | 2017-03-16 | — | — | US | claimed |
| US-5013742-A | Analgesics, Anesthetics, Narcotic Antagonists | BOC, INC. (US) | 1991-05-07 | — | — | US | claimed |
| EP-4727556-A2 | SEQUESTRANT COMPOUNDS FOR ALPHA 2 ADRENERGIC AGONISTS | Clear Scientific, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| US-12527770-B2 | Methods of managing pain using dexmedetomidine transdermal delivery devices | TEIKOKU PHARMA USA, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12529695-B2 | Fentanyl analogue detection methods and kits thereof | VERITEQUE USA, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20140190496-A1 | METHODS AND DEVICES FOR COMPOUND DELIVERY | E-NICOTINE TECHNOLOGY, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| WO-2014085719-A1 | METHODS AND DEVICES FOR COMPOUND DELIVERY | E-NICOTINE TECHNOLOGY, INC. (US) | 2014-06-05 | — | — | WO | disclosed |
| US-20140144429-A1 | METHODS AND DEVICES FOR COMPOUND DELIVERY | E-NICOTINE TECHNOLOGY, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| EP-0869791-B1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170071851-A1 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | OPRL1, OPRM1, OPRK1 | OPRM1 2/4885OPRD1 4/4885OPRK1 3/4885 |
| US-20210093557-A1 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | OPRL1, OPRM1, OPRK1 | OPRM1 2/4885OPRD1 4/4885OPRK1 3/4885 |
| US-12529695-B2 | Fentanyl analogue detection methods and kits thereof | CA13, CA2, CA12 | OPRM1 24/4885OPRD1 6/4885OPRK1 19/4885 |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | PFKP, PBK, MYLK | OPRM1 4810/4885OPRD1 4518/4885OPRK1 2862/4885 |
| US-12527770-B2 | Methods of managing pain using dexmedetomidine transdermal delivery devices | OPRD1, OPRK1, OPRM1 | OPRM1 3/4885OPRD1 1/4885OPRK1 2/4885 |
| US-20200030229-A1 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | OPRL1, OPRM1, OPRK1 | OPRM1 2/4885OPRD1 4/4885OPRK1 3/4885 |
| US-10085937-B2 | Nasal drug products and methods of their use | OPRL1, OPRM1, OPRK1 | OPRM1 2/4885OPRD1 4/4885OPRK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.